FLT3 and acute myeloid leukemia: Mounting evidence implicates SMO-independent, non-canonical ways of GLI activation by alternative oncogenic pathways in AML, including FLT3-ITD, PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signaling cascades [2,3].